Endometrial Cancer

Phase 3 trial results presented at the #ASCOPlenarySeries show that selinexor has the potential to extend progression-free survival in patients with wild-type TP53 advanced or recurrent #EndometrialCancer. @ASCO @OBRtweets @GynCancerMD https://t.co/Dek5NNgoxY (@AaronTallent)

Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy. @GynCancerMD @MountSinaiMiami #gyncsm https://t.co/2uFIB9qa1N (@OncLive)

JUST IN: @FDAOncology approved dostarlimab (PD-1 inh, GSK) w/carboplatin+paclitaxel, followed by single-agent dostarlimab, for dMMR/MSI-H metastatic endometrial cancer. Approval based on RUBY trial published in @NEJM 2023 https://t.co/QAkLNAnmWy @OncoAlert @OncBrothers (@DrChoueiri)

WATCH: Dr Mirza on the FDA Approval of Dostarlimab Plus Chemotherapy in dMMR/MSI-H Endometrial Cancer @MirzaCPH @Rigshospitalet @US_FDA #gyncsm https://t.co/znzrC40eHt (@OncLive)

FDA Approves Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer https://t.co/cJNILT0V1t via @targetedonc #MedTwitter #OncTwitter #ecsm (@dawood_findakly)

Hot in #JITC - #ICYMI: Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA dMMR/MSI-H or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study https://t.co/CFWk7OrrN7 @AnaOaknin @BPothuri (@jitcancer)

Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy. @GynCancerMD @MountSinaiMiami #gyncsm https://t.co/Yqx4ujHYxL (@OncLive)

A subgroup of patients with TP53 wild-type advanced/recurrent endometrial cancer experienced a long-lasting improvement in progression-free survival following treatment with maintenance selinexor vs placebo. #gyncsm | @GynCancerMD @ASCO https://t.co/MhThvOPnAr (@CancerNetwrk)

Maintenance Selinexor Shows Potential Improved PFS Signal in TP53 Wild-Type Endometrial Cancer https://t.co/09CnhGXXFi #gyncsm PFS of patients taking maintenance selinexor was 27.4 months compared with 5.2 months placebo. @GynCancerMD are studies planned in HGOC population? (@womenofteal)

🚨NEW!🚨#CancerResearch #ASCOPlenarySeries – A study from @GynCancerMD evaluates using maintenance therapy with #Selinexor to treat people with advanced or recurrent TP53 wild-type #EndometrialCancer https://t.co/PHsLLpuB1O #GyncSM #UterineCancer (@CancerDotNet)

Selinexor Maintenance After First-Line Chemotherapy Extends PFS in TP53 Wild-Type Advanced Endometrial Cancer @GynCancerMD @MountSinaiMiami @ASCO #gyncsm https://t.co/FIfHtAQZAx (@OncLive)

Join us #IJGCclub 📅July 25 ⏲️11am CT/6pm CET Dr Capozzi will discuss about the outcomes in #EndometrialCancer patients undergoing SLNB vs lymphadenectomy 📄 https://t.co/dz0gRZOE4l @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @IJGCfellows (@IJGConline)

Looking for insight into the accumulating data that support the use of ICIs in patients with advanced #EndometrialCancer? Watch this video featuring experts David M. O'Malley, MD,@AnaOaknin & Matthew A. Powell, MD: https://t.co/wmdHecNmNs #ASCO23 #MedEd #MedTwitter (@PeerView)

What part can hormone therapy play in #endometrialcancer treatment? Dr. Hoskins @drebonyhoskins of @MedStarWHC shares situations that often work well with this therapy. https://t.co/LqeqmO6PEW #gyncsm (@power4patients)

Study on phase I trial efficacy and safety of #dostarlimab in patients with advanced or recurrent #EndometrialCancer and analysis of tumor #biomarkers as prognostic indicators by Oaknin et al. https://t.co/bIYQrWUY5L @CaraMath @ValentinaBoni7 @BanerjeeSusana @AACR (@CCR_AACR)

🇳🇴 study: self-reported lower extremity #lymphedema and #QualityOfLife after surgical staging of endometrial carcinoma @BjerreTrent @jebens_nina @agz_eriksson @SGO_org @IGCSociety @ESGO_society @OncoAlert @ASCO @myESMO https://t.co/GixR5v4k9e (@gynoncjnls)

Love this article by @NicoloBizzarri @frafanfani My main question is: Can we asume the 50% sensitivity is all caused by a sampling bias and just go ahead with OSNA? If not… how to eliminate this bias in a future study? #osna #endometrialcancer @pedroramirezMD @leitaomd (@BoriaFelix)

1/ #ECBrief irAE monitoring & management in #endometrialcancer w/ @DrMMurphy & @MeganLeigh127 Supported by an educational grant from Merck. CME ℹ️ https://t.co/lWqE0j33IC 📊What is your specialty/degree❓ (@SoMeCME)

4/ 💬 What irAEs can be expected in patients with #endometrialcancer❓ What is the best approach to irAE monitoring & management❓ @DrMMurphy will tell you all about it in the video below! #ECBrief https://t.co/GgXqWt7HfU (@SoMeCME)

5/ 📊 After watching @DrMMurphy's video, what approach would you take to manage asymptomatic or symptomatic, grade 1 or 2 hypothyroidism in a woman w/ #endometrialcancer who is receiving pembrolizumab treatment❓ #ECBrief (@SoMeCME)

Do you have any irAE management pearls for patients taking IO for #endometrialcancer? #gyncsm @Bhandoria @IJGConline @FBackesMD @ArendRebecca @BarbaraAGoff @ArchiMed24 @jscalici @Doctor_Beryl @bjdmatthews @RiosDoriaMD @TeresaBoitano @dholakiamd @delararitchie @uppals (@MeganLeigh127)

How frequently do you monitor for irAE? 🤔 #gyncsm #endometrialcancer @RiosDoriaMD @LoganCoreyMD @gyoedu @BPothuri @ShannonWestin @amandanfader @StephanieVBlank @LAMcAlarnenMD @drteplinsky @drdonsdizon (@MeganLeigh127)

Some @SoMeCME for your Wednesday Hump Day 🐫! Tune in for some high yield discussion about irAE in #EndometrialCancer #SoMeCME #CME #OncTwitter #MedTwitter @RiosDoriaMD @LoganCoreyMD @gyoedu @BPothuri @ShannonWestin @amandanfader @StephanieVBlank @LAMcAlarnenMD @drteplinsky (@MeganLeigh127)

New evidence on the accuracy of OSNA in endometrial cancer SLN study! Congrats! @NicoloBizzarri @frafanfani 🔎🔜 Is this the future of SLN ultrastaging? @IJGCfellows @IJGConline @ENYGO_official @JayrajAarthi @HsuMd @pedroramirezMD @agz_eriksson @AndreFernandes2 (@Cucinella_G)

Read about the #diagnostic accuracy of #OSNA in detection of #SLN metastasis in #endometrial #cancer 🔗 https://t.co/ISWKZbqKdY @NicoloBizzarri @frafanfani @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @agz_eriksson @IGCSociety @ESGO_society @ENYGO_official @OncoAlert… https://t.co/85hqldbthZ (@IJGConline)

Submit an abstract by September 1 for the AACR Special Conference on Endometrial Cancer: Transforming Care Through Science (November 16-18, Boston), chaired by Victoria L. Bae-Jump, Deborah F. DeLair, and Douglas A. Levine. Learn more: https://t.co/8RGN32ttnN #AACRec23 @levinemd (@AACR)

#Pembrolizumab plus #Chemotherapy in Advanced #EndometrialCancer 👉https://t.co/j9SQBGqkC6 @NEJM @Rne_md @CarryAghaj (@davidhenrymd)

Microsatellite instability in non-colorectal & non-endometrial malignancies in patients with Lynch syndrome @JNCI_Now https://t.co/oW2kfivE38 👉85% of Lynch-spectrum tumors are MSI-H/dMMR 👉37% of non–Lynch-spectrum cancers are MSI-H/dMMR @myESMO @OncoAlert (@ArndtVogel)

Small steps leading to one giant leap! Amazing presentation by @MirzaCPH at European Masterclass on #EndometrialCancer! (@OraianthiF)

#GSK Satellite Symposium Controversies in Ovarian and Endometrial Cancer. Imagining the Management of These Patients #IAOC2023 https://t.co/k808kQDiBI @AnaOaknin Dr Gonzalo Gómez Abuin (@IAOC_Conference)

NRG-GY012 Study Tests Multiple Olaparib Combinations in Endometrial Cancer https://t.co/iA3GZYAvc7 via @targetedonc (@NCCH_MD)

Looking forward to presenting the long term Siendo data @ASCO virtual plenary. We continue to make progress to help our patients with #endometrialcancer @Karyopharm @IGCSociety @SGO_org @NRGonc @IJGConline @MountSinaiMiami @GOG @rcoledude @pedroramirezMD (@GynCancerMD)

Mark your calendars for a fantastic July @ASCO Plenary Series session! 📍Series Chair @DrChoueiri and Session Faculty @DrHelenMacKay @GynCancerMD & Gini Fleming MD will cover the phase 3 SIENDO study of maintenance selinexor vs placebo for adv/recurrent #endometrialcancer… https://t.co/3nZNNCqKH2 (@IshwariaMD)

Mark your calendars for a fantastic July @ASCO Plenary Series session! 📍Series Chair @DrChoueiri and Session Faculty @DrHelenMacKay @GynCancerMD & Gini Fleming MD will cover the phase 3 SIENDO study of maintenance selinexor vs placebo for adv/recurrent #endometrialcancer… https://t.co/P8N0IiuvcE (@IshwariaMD)

July #ASCOPlenarySeries to ft. Long-term follow up of selinexor maintenance in pts w TP53wt adv. or recurrent #EndometrialCancer: A pre-specified subgroup analysis from Ph3 ENGOT-EN5/GOG-3055/SIENDO study 📅 When: 7/25 🔗 https://t.co/3RdAQrUEEO @OncoAlert #gyncsm @GynCancerMD (@ASCO)

Happening on July 25. We are back ! The @ASCO #ASCOPlenarySeries are back Randomized maintenance trial in endometrial cancer with an amazing panel! Be there ! “Because Science can’t wait” @OncoAlert https://t.co/HyTbUDOuu7 (@DrChoueiri)

Nice editorial by @AndreasObermair to reflect on SLNB in (high-risk) endometrial cancer 📌https://t.co/9zAkRb5AZ3 @pedroramirezMD @IJGConline @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 (@GuidoReyv)

Read the editorial on SLN in high-risk endometrial cancer by @AndreasObermair and be prepared for the next journal club discussion! https://t.co/dqFf2nvHfQ @IJGConline @ENYGO_official @ESGO_society @IGCSociety @BGCS_org @BgcsFellows @agz_eriksson @pedroramirezMD @HsuMd (@IJGCfellows)

Controversies in Ovarian Cancer at GSK Satellite Symposium at the 10th IAOC Conference #OvarianCancer #EndometrialCancer @AnaOaknin Dr. Gonzalo Gómez Abuin (@IAOC_Conference)

Prudent editorial by @AndreasObermair about #sentinelnode in #endometrialcancer Should gynoncs refrain from their typical neophilia and undoubtable savings in time and side effects from ICG mapping til 2028? https://t.co/6mSh8sQJng (@dragibert)

Don’t miss the opportunity to read the #leadarticle about SLN in high-risk #EndometrialCancer 📚 Congrats to @frafanfani and the team for the great work! @IJGCfellows @pedroramirezMD @HsuMd @ENYGO_official (@Cucinella_G)

#LeadArticle Long-term survival outcomes in high-risk #EndometrialCancer patients undergoing SLN biopsy alone vs lymphadenectomy @frafanfani 📌 https://t.co/aC8fHWUd0s @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @OncoAlert @IJGCfellows (@IJGConline)